Overview

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Status:
Completed

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3 activating mutations.

Phase:

Phase 2

Details

Lead Sponsor:

Arog Pharmaceuticals, Inc.

Treatments:

Crenolanib
Cytarabine
Daunorubicin
Idarubicin